Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KRAS
Biotech
Chinese biotech helmed by AZ veteran reels in $108M series B
D3 Bio will use the funds to advance its lead KRAS inhibitor into phase 3 studies.
James Waldron
Dec 10, 2025 3:45am
Bayer picks Kumquat for $1.3B KRAS collaboration
Aug 12, 2025 6:29am
At ASCO, execs see chance to ‘rewrite textbooks’ in cancer care
Jun 2, 2025 9:45am
BridgeBio's cancer spinout backs SPAC as path to Nasdaq
Feb 28, 2025 9:25am
High dose of Cardiff's KRAS drug shows 64% ORR, sending stock up
Dec 10, 2024 4:05pm
Roche culls cough candidate, pivots KRAS program in Q3 update
Oct 23, 2024 6:35am
